- Home
- BKD vs IMCR Comparison
BKD vs IMCR Comparison
Compare BKD & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKD
- IMCR
- Stock Information
- Founded
- BKD 2005
- IMCR 2008
- Country
- BKD United States
- IMCR United Kingdom
- Employees
- BKD N/A
- IMCR N/A
- Industry
- BKD Hospital/Nursing Management
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BKD Health Care
- IMCR Health Care
- Exchange
- BKD Nasdaq
- IMCR Nasdaq
- Market Cap
- BKD 1.5B
- IMCR 1.5B
- IPO Year
- BKD 2005
- IMCR 2021
- Fundamental
- Price
- BKD $6.38
- IMCR $38.65
- Analyst Decision
- BKD Buy
- IMCR Buy
- Analyst Count
- BKD 5
- IMCR 10
- Target Price
- BKD $7.70
- IMCR $58.13
- AVG Volume (30 Days)
- BKD 2.7M
- IMCR 462.7K
- Earning Date
- BKD 05-06-2025
- IMCR 05-07-2025
- Dividend Yield
- BKD N/A
- IMCR N/A
- EPS Growth
- BKD N/A
- IMCR N/A
- EPS
- BKD N/A
- IMCR N/A
- Revenue
- BKD $3,015,786,000.00
- IMCR $333,581,000.00
- Revenue This Year
- BKD $8.43
- IMCR $25.96
- Revenue Next Year
- BKD N/A
- IMCR $8.06
- P/E Ratio
- BKD N/A
- IMCR N/A
- Revenue Growth
- BKD 4.14
- IMCR 25.75
- 52 Week Low
- BKD $4.45
- IMCR $23.15
- 52 Week High
- BKD $8.12
- IMCR $48.50
- Technical
- Relative Strength Index (RSI)
- BKD 45.12
- IMCR 75.29
- Support Level
- BKD $6.31
- IMCR $31.14
- Resistance Level
- BKD $6.60
- IMCR $33.30
- Average True Range (ATR)
- BKD 0.19
- IMCR 2.03
- MACD
- BKD -0.06
- IMCR 0.79
- Stochastic Oscillator
- BKD 15.83
- IMCR 94.68
About BKD Brookdale Senior Living Inc.
Brookdale Senior Living Inc operates senior living communities throughout the United States. The company has three reportable segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRs). The majority of the revenue is generated from the Assisted Living and Memory Care segment, which offers housing and assistance with activities of daily living to its customers. The company generates revenue in the form of Resident Fees, which it receives in exchange for the services provided, and in the form of management fees from certain communities under contract in exchange for the management services provided.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.